Pembrolizumab (Keytruda) 100mg/4mL | China-Sourced | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

Share
Product description

Generic Name: Pembrolizumab
Salt Name: Pembrolizumab (recombinant humanized anti-PD-1 monoclonal antibody)
Availability: On Request
Manufacturer: Merck Sharp & Dohme | China-Mainland
Strength: 100mg/4mL injection

What is Pembrolizumab (Keytruda) Used For?

Pembrolizumab is a humanized monoclonal antibody that targets the PD-1 receptor on T-cells, blocking the immune checkpoint and allowing the immune system to attack cancer cells. It is FDA- and NMPA-approved for the treatment of multiple cancers including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, hepatocellular carcinoma, microsatellite instability-high (MSI-H) cancers, and many others.

What is Pembrolizumab?

Keytruda (pembrolizumab) is one of the most widely used PD-1 inhibitors in the world. It works by binding to PD-1 and releasing the brake on the immune system, enabling T-cells to recognize and destroy tumor cells. The China-Mainland version of Keytruda is manufactured by Merck Sharp & Dohme and distributed in China, where it has become one of the most affordable authorized versions globally after being included in China's National Reimbursement Drug List (NRDL).

NMPA-Approved Indications

China-Mainland Keytruda is currently approved by the National Medical Products Administration (NMPA) for the following indications (as of latest NRDL update):

  • Non-small cell lung cancer (NSCLC) — first-line monotherapy for PD-L1 positive tumors (TPS ≥1%)
  • NSCLC in combination with chemotherapy for squamous and non-squamous histology
  • Melanoma — advanced and adjuvant treatment
  • Head and neck squamous cell carcinoma (HNSCC)
  • Classical Hodgkin lymphoma (cHL) — relapsed/refractory
  • Urothelial carcinoma — advanced/metastatic
  • Gastric and gastroesophageal junction adenocarcinoma
  • Hepatocellular carcinoma (HCC)
  • Microsatellite instability-high (MSI-H) or dMMR solid tumors
  • Cervical cancer
  • Esophageal cancer

Dosage & Administration

The recommended dose of Pembrolizumab is 200 mg every 3 weeks or 400 mg every 6 weeks, administered as an intravenous infusion over 30 minutes. Treatment continues until disease progression or unacceptable toxicity. Always follow the prescribing oncologist's instructions.

Common Side Effects

The most common adverse reactions (≥20%) include fatigue, decreased appetite, pruritus, rash, diarrhea, nausea, and musculoskeletal pain. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis, and endocrinopathies may occur and require prompt medical attention. Patients should be monitored regularly by their treating oncologist.

Storage

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake. The China-Mainland product is supplied as a single-dose vial containing 100 mg of pembrolizumab in 4 mL of solution.

Why Choose China-Sourced Keytruda?

China's National Reimbursement Drug List (NRDL) negotiations have made Keytruda one of the most cost-effective authorized versions worldwide. The China-Mainland version is the same molecule, manufactured by Merck under the same quality standards, but priced significantly lower than the US, EU, and Hong Kong versions. For patients and institutions seeking affordable yet authentic Keytruda, the China-sourced option is often the most accessible.

  • Same manufacturer (Merck) as US/EU versions
  • NMPA-approved in China, with full regulatory documentation
  • Significantly lower cost than US/EU prices (often 30-50% lower)
  • Global export by Hong Kong-licensed wholesaler with full documentation

Quality Assurance

All China-Mainland Keytruda supplied by GIVE LIFE TIME LIMITED is sourced directly from authorized Merck channels, with full batch traceability, Certificate of Analysis (COA), and Chinese NMPA documentation. Every shipment includes export-ready documentation: commercial invoice, packing list, and Certificate of Origin.

How to Order

To request pricing and place an order for China-Mainland Keytruda, please follow these steps:

  1. Send your prescription or case file via WhatsApp or email — we will review it within 24 hours
  2. Receive a formal quotation with detailed pricing, availability, and shipping options
  3. Confirm and arrange payment via bank transfer or PayPal
  4. Ship globally with full export documentation and tracking

Send your prescription / case file now: WhatsApp: +86 15234153837

Frequently Asked Questions

What is the difference between China-sourced and US-sourced Keytruda?

Both are manufactured by Merck under the same quality standards. The active ingredient (pembrolizumab) is identical. The difference is the market they are distributed in: the China version is priced lower due to NRDL negotiations, while the US version is priced higher. For international patients, the China version is often the most affordable authorized option.

Is a prescription required to order China-sourced Keytruda?

Yes. Keytruda is a prescription-only medicine. A valid prescription from a licensed oncologist is required. Please send your prescription or case file via WhatsApp before ordering.

How long does international shipping take?

Most international orders are dispatched within 3-5 business days after payment confirmation, with delivery times of 7-14 business days depending on the destination country and customs clearance.

Do you ship Keytruda with cold-chain logistics?

Yes. Keytruda requires temperature-controlled shipping (2-8°C) and is packed in validated cold-chain packaging. We coordinate with specialized pharmaceutical couriers for international deliveries.

Can you help with customs clearance for personal-use imports?

Yes. We provide all necessary export documentation and can support Named Patient Program (NPP) requirements for many destination countries. Customs and import regulations vary by country — please consult with us before ordering.

Related Oncology Products

KeZeRui 科瑞泽 (Avatrombopag) 20mg*10 Tablets | Sichuan Kelun China | GLT

KeZeRui — national-procurement avatrombopag from Sichuan Kelun Pharmaceutical, China's integrated API + tablet maker

Olumiant (Baricitinib) 2mg/4mg Tablets | JAK1/JAK2 Inhibitor | Eli Lilly USA | GLT

Eli Lilly's selective JAK1/JAK2 inhibitor for rheumatoid arthritis, atopic dermatitis and severe alopecia areata.

Tixepa (Tirzepatide) 20mg/2mL & 30mg/2mL Multi-Dose Pen | Drug International | GLT

Tixepa — Drug International Limited (DIL) tirzepatide multi-dose pen, two official strengths (Tixepa-5 = 20mg/2mL,...

Mounjaro KwikPen (Tirzepatide) 10–60mg/2.4mL Multi-Dose | Eli Lilly USA | GLT

Mounjaro KwikPen — Eli Lilly single-patient multi-dose pen, six US strengths (10–60mg/2.4mL, 4 doses each)...

Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Lucius Pharmaceuticals (Laos) generic orforglipron, 6-dose titration for weight management

KangQuXin 康曲欣 (Avatrombopag) 20mg*10 Tablets | Beijing Continent Gyre | GLT

KangQuXin — avatrombopag by Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), China Mainland

Orforglipron (OriYo) 0.8–17.2mg Tablets | Bangladesh Generic Oral GLP-1 | GLT

National Drug Co. generic orforglipron, 6-dose titration for weight management

Barinat (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Natco Pharma Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Natco Pharma Limited (India) — an affordable alternative to Olumiant...